Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Other financing activities (2017 - 2021)

Usana Health Sciences (USNA) has disclosed Other financing activities for 12 consecutive years, with $4.2 million as the latest value for Q2 2022.

  • On a quarterly basis, Other financing activities changed N/A to $4.2 million in Q2 2022 year-over-year; TTM through Dec 2022 was $4.2 million, a N/A change, with the full-year FY2021 number at $46000.0, down 97.68% from a year prior.
  • Other financing activities was $4.2 million for Q2 2022 at Usana Health Sciences, up from -$1.9 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.2 million in Q2 2022 to a low of -$1.9 million in Q1 2021.
  • A 5-year average of $655083.3 and a median of $143500.0 in 2018 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 1500.0% in 2018; the steepest drop was 218.61% in 2018.
  • Usana Health Sciences' Other financing activities stood at -$376000.0 in 2018, then skyrocketed by 611.17% to $1.9 million in 2019, then tumbled by 97.76% to $43000.0 in 2020, then crashed by 4506.98% to -$1.9 million in 2021, then surged by 322.22% to $4.2 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Other financing activities are $4.2 million (Q2 2022), -$1.9 million (Q1 2021), and $43000.0 (Q3 2020).